Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies

Frontiers in Medicine
Luca PetriccaElisa Gremese

Abstract

Systemic lupus erythematosus (SLE) and bullous pemphigoid (BP) are chronic autoimmune diseases in which B cells play an important pathogenic role in the different stages of the disease. B cell-targeted therapies have been suggested as a new rational approach for treating SLE. Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, failed to achieve primary endpoints in two clinical trials (EXPLORER and LUNAR) despite multiple observational and retrospective studies showing its beneficial effect on SLE. Moreover, RTX is recommended in cases of BP that is unresponsive to conventional treatments. Belimumab (BLM), a human immunoglobulin G1 λ monoclonal antibody that inhibits soluble B-lymphocyte stimulator (BlyS)/B-cell activating factor (BAFF), is the only biological treatment approved for standard therapy of refractory autoantibody-positive active SLE. Animal models and a few case reports have supported the efficacy of the combined use of RTX followed by BLM as maintenance therapy in severe lupus nephritis (LN), suggesting that their combined use may be more effective than their single use, without compromising safety. In this study, we describe the clinical case of a SLE patient with predominant renal involvement in overlap ...Continue Reading

References

Aug 1, 1982·Journal of the American Academy of Dermatology·C A Clayton, T K Burnham
Feb 1, 2002·The New England Journal of Medicine·Pascal JolyUNKNOWN Bullous Diseases French Study Group
Jan 30, 2004·Journal of the American Society of Nephrology : JASN·Jan J WeeningMichio Nagata
Jul 6, 2010·Journal of Immunological Methods·Thomas DörnerPeter E Lipsky
Oct 29, 2011·Autoimmunity Reviews·Cándido Díaz-LagaresUNKNOWN UK-BIOGEAS Registry
Aug 2, 2012·Annals of the Rheumatic Diseases·George K BertsiasUNKNOWN European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association
Dec 26, 2012·Revista Clínica Espanõla·M Ramos-CasalsUNKNOWN Comité de Consenso sobre el uso de belimumab, Grupo de Trabajo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Sociedad
Mar 16, 2013·Current Opinion in Rheumatology·Ziv Paz, George C Tsokos
Apr 19, 2013·The New England Journal of Medicine·Bevra Hannahs Hahn
Sep 11, 2014·Rheumatology·Tineke KraaijY K Onno Teng
Feb 19, 2016·Nature Reviews. Rheumatology·Michael R Ehrenstein, Charlotte Wing
May 31, 2016·Joint, Bone, Spine : Revue Du Rhumatisme·Federico SimonettaCarlo Chizzolini
Sep 22, 2016·Lupus Science & Medicine·Monica Rydén-AulinRonald van Vollenhoven
Nov 23, 2016·Nature Reviews. Rheumatology·George C TsokosKathleen E Sullivan
Mar 30, 2017·The American Journal of Case Reports·Maria Cristina MaggioRolando Cimaz
Aug 24, 2017·Clinical and Experimental Immunology·G Ferraccioli, E Gremese
Aug 31, 2017·Archives of Dermatological Research·Agnieszka Kalinska-BieniasKatarzyna Wozniak
Apr 11, 2018·Journal of Autoimmunity·Tineke KraaijY K Onno Teng
Mar 31, 2019·Annals of the Rheumatic Diseases·Antonis FanouriakisDimitrios T Boumpas
Sep 17, 2020·The New England Journal of Medicine·Richard FurieDavid A Roth

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies

Clinical Trials Mentioned

NCT01639339
NCT02260934
NCT02284984

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.